OncoDNA launches OncoDEEP® Kit for comprehensive biomarker testing of solid tumors

Unique workflow solution integrating a comprensive pan-cancer NGS panel powered by Twist Bioscience and a bioinformatics software suite.

OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases, announced today the launch of the OncoDEEP Kit. The kit offers a complete workflow solution which enables laboratories with NGS capabilities to perform comprehensive biomarker testing, provide powerful data analysis and support oncologists in the most effective and personalized treatments for their cancer patients. The OncoDEEP Kit integrates both reagents and quality control standards for the sequencing of over 600 cancer biomarkers. The offer will come in combination with OncoDNA’s data analysis and clinical interpretation tools for the rapid analysis and reporting of a patient’s tumor molecular profile. OncoDEEP Kit is available for early access and will be commercially available by the end of Q2 2022.

The OncoDEEP kit leverages OncoDNA’s extensive experience in precision oncology and is optimized for the reliable analysis of somatic variants and translocations while also facilitating the measurement of complex genomic signatures such as homologous recombination deficiency (HRD), a predictive biomarker for cancer therapy with PARP inhibitors. The kit also enables the measurement of tumor mutational burden (TMB), microsatellite instability (MSI) and loss of heterozygosity (LOH).

OncoDNA has offered the OncoDEEP tissue-based biomarker test as a centralized laboratory developed test since 2014. Compared to single biomarker tests, the OncoDEEP test covers a comprehensive panel of genes and phenotypes known to be associated with cancer therapies – an approach used to determine in a single test if a patient may potentially respond to specific cancer drugs or clinical trials.

The OncoDEEP kit, which incorporates Twist Bioscience’s enrichment and library preparation solutions, will provide laboratories access to a reliable and complete solution for performing comprehensive NGS analysis of tumor samples. With this new offering, even laboratories with limited bioinformatics capabilities will have the combined ability to perform large panel sequencing, obtain the molecular characterization of a tumor, analyze the raw data and access extensive quality controls utilizing MERCURY™, OncoDNA’s secure, cloud-based software tool. OncoDNA will also be able to run the sequencing data through its proprietary database and extract patient-specific clinical interpretation reports made available on its OncoKDM® online platform. To date, its database counts no less than 4,500,000 genetic variants, 1,150 cancer drugs, and data from 7,000 clinical trials.

“We are excited to transfer our knowledge and facilitate the routine use of comprehensive biomarker testing to other laboratories,” stated Jean-Pol Detiffe, Chief Strategy and Innovation Officer, and Founder of OncoDNA. “While OncoDEEP has been our flagship biomarker test over the past years, we see more and more laboratories adopting NGS technology and becoming interested in utilizing our test in-house. We believe that this decentralized version of OncoDEEP will be a very attractive proposition for numerous hospitals. Combined with our bioinformatics software suite, the OncoDEEP kit will enable them to identify a broader set of treatment options for their patients, while saving on time and cost of outsourcing.”

Koen Jacobs, molecular biologist at AZ Sint-Lucas Gent and beta tester, commented: “We see biomarkers such as HRD and MSI play an increasingly essential role in precision medicine, however, the development and validation of pan-cancer bioanalytical methods remain burdensome. With its OncoDEEP kit, OncoDNA provides us with the appropriate tools to analyze such complex biomarkers. I feel confident that it will help us access critical insights to drive precision medicine.”
As next-generation sequencing becomes a mainstream technology and precision medicines proliferate, more and more hospitals have brought NGS testing in-house to guide personalized treatment decisions. By making its technology and expertise available, OncoDNA aims to support their NGS efforts, enabling hospitals to profile a large number of biomarkers and improve access to precision medicines.


OncoDNA is a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The company helps clinicians, academic researchers and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine. The company not only provides clinical guidance for the treatment and real-time monitoring of late stage cancer patients, but also supports research and drug development in cancer and genetic diseases. Since its early days in 2012, OncoDNA grew into a corporate group of companies with world-renown expertise. The Group offers a unique portfolio that combines NGS services, biomarker testing, data analysis software and clinical decision support tools. OncoDNA is headquartered in Belgium, and its entities – BioSequence and IntegraGen – are based in Spain and France. The Group employs over 100 employees across 9 countries, works with an international network of 35 distributors and collaborates with both European-based and US-based subcontracted accredited laboratories.
For further information, connect with us on LinkedInFacebook.



Koenraad EYCKEN
Chief Product Officer

You may also be interested in these resources

Scientific Application Note

LUNG CANCER: Data from TRACERx presented at AACR provides further support for the use of personalised ctDNA assays in the assessment of minimal residual disease and impending progression following surgery for early stage disease

CT023 – Phylogenetic tracking and minimal residual disease detection using ctDNA in early-stage NSCLC: A lung TRACERx study AACR Annual Meeting 2020 Online Proceedings and Itinerary Planner Home April 28, 2020 ABSTRACT INTRODUCTION  Minimal residual disease...

Share This